The GNRH1 Knockout 786-O Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal population derived from the human 786-O renal cell adenocarcinoma line, designed for loss-of-function studies of the gonadotropin-releasing hormone (GNRH1) gene. This product provides a heterogeneous cell pool carrying targeted gene disruption, enabling researchers to investigate the phenotypic consequences of GNRH1 ablation without selecting a single clonal isolate. The polyclonal format preserves biological variability while ensuring robust knockout representation across the population, making it suitable for unbiased functional assays in a cell model relevant to renal cancer biology.
The host 786-O cell line was established from a primary clear cell renal cell carcinoma (ccRCC) and harbors an endogenous VHL tumor suppressor mutation, recapitulating the most common genetic alteration in sporadic ccRCC. These adherent epithelial cells serve as a standard preclinical model to study renal carcinoma signaling, drug responses, and tumor progression mechanisms. Their well-characterized genetic background and compatibility with a wide range of molecular and cellular assays provide a physiologically relevant system for dissecting gene function in a cancer context marked by dysregulated hypoxia and growth factor pathways.
GNRH1 encodes the preprohormone that is proteolytically processed by PCSK1 and PCSK2 to yield the GnRH decapeptide, which signals through its cognate receptor GNRHR. Canonically, GnRH binding to GNRHR on pituitary gonadotropes activates the GNAQ/GNA11?CPLC?? axis, generating inositol trisphosphate and diacylglycerol to mobilize calcium and stimulate PRKCA. This cascade converges on the MAPK/ERK pathway, where RAF1?CMAP2K1/2?CMAPK1/3 (ERK1/2) phosphorylate transcription factors such as CREB1 and JUN, driving expression of LHB and FSHB. In 786-O renal cancer cells, GNRH1 may also engage non-classical pathways, including JNK and p38 MAPK, to exert an antiproliferative influence. Upstream regulators such as KISS1, estradiol, and progesterone modulate GNRH1 expression, highlighting the integration of hormonal cues with tumor cell signaling.
The introduction of GNRH1 knockout in 786-O cells disrupts autocrine/paracrine GnRH signaling that may normally restrain cell proliferation in the VHL-mutant renal tumor microenvironment. Loss of GnRH-mediated activation of MAPK/ERK, calcium, and apoptosis-associated pathways can alter cell cycle progression, viability, and migration, offering a direct model to examine the hormone??s growth-inhibitory functions in ccRCC. Given the emerging roles of neuropeptide hormones in cancer biology, this engineered polyclonal population provides a valuable tool for exploring how GNRH1 integrates with oncogenic and tumor-suppressive networks, potentially revealing vulnerabilities for therapeutic intervention.
Researchers can employ this model to investigate GnRH signaling in renal cell carcinoma, test pharmacological GnRH analogs (agonists or antagonists) for antitumor effects, and conduct transcriptome-wide analyses to map GNRH1-dependent gene signatures. Typical assays include RT-qPCR and western blotting to confirm knockout and assess downstream targets (e.g., ERK1/2, CREB1, c-FOS); calcium flux assays and phospho-ERK ELISA to measure pathway activation; MTT and Annexin V staining for viability and apoptosis; Transwell migration assays to evaluate invasiveness; and RNA-seq for global expression profiling. For further information, please contact Ascent Research.
